In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

The companies aim to generate preclinical proof-of-concept data on SRB123 and quickly take it into clinical trials.

OCCAM Immune, a Mount Sinai research organization, will sequence and map cells from samples collected in CRI's immunotherapy trials.

The funds will support the firm's lead programs, ABS-1230 for KCNT1-related epilepsy and ABS-0871 for TRPV4-positive Charcot-Marie-Tooth disease type 2C.

The partners have committed to awarding two grants, totaling around $2.3 million, to researchers studying this lung cancer subset.

Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.

The project will leverage Noetik's AI model and multimodal spatial data to search for biomarkers of patient response to Agenus' immunotherapy regimen.

Studies doing genome-wide testing can easily ID patients with naturally low neutrophil counts, but nobody's looking at it, ...

The firm is developing the PHOX2B-targeted cell therapy, which has shown promise in preclinical xenograft models, with CHOP researchers.

The firm will stop shipping the gene therapy for these patients until a new immunosuppressive regimen is approved for managing acute liver failure.

The firm will assess irpagratinib plus best supportive care in patients with FGF19-overexpressing advanced liver cancer.

The agency approved a perioperative Keytruda regimen based on a 30 percent reduction in the risk of recurrence, progression, or death versus the control arm.